LYNDHURST, N.J., June 7 /PRNewswire-FirstCall/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,
information and services, announced today that it has signed a multi-year
contract extension with CIGNA HealthCare and will remain a participating
provider in all markets for all products. Quest Diagnostics is the largest
provider of laboratory services to CIGNA HealthCare, providing its members and
providers with the nation's broadest access to laboratory services. Financial
terms were not disclosed.
"We are very pleased to continue to serve CIGNA HealthCare's members and
providers across the country," said Surya N. Mohapatra, Ph.D., Chairman and
Chief Executive Officer, Quest Diagnostics. "CIGNA HealthCare continues to
offer its providers choice in laboratory services, and we are delighted to
compete on the basis of the quality and service we provide."
Quest Diagnostics is the leading provider of diagnostic testing,
information and services that patients and doctors need to make better
healthcare decisions. The company offers the broadest access to diagnostic
testing services through its national network of laboratories and patient
service centers, and provides interpretive consultation through its extensive
medical and scientific staff. Quest Diagnostics is a pioneer in developing
innovative new diagnostic tests and advanced healthcare information technology
solutions that help improve patient care. Additional company information is
available at: http://www.questdiagnostics.com
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results and
outcomes to be materially different. Certain of these risks and uncertainties
may include, but are not limited to, competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other factors described in the Quest
Diagnostics Incorporated 2006 Form 10-K and subsequent SEC filings.
SOURCE Quest Diagnostics
CONTACT: Investors, Laure Park, +1-201-393-5030, Media, Nancy
Fitzsimmons, +1-201-393-5700, both of Quest Diagnostics
Web site: http://www.questdiagnostics.com